Photo by nci from unsplash
Highlights • The glutamine utilization of KRAS-mutant NSCLC is higher than that of KRAS wild-type.• Targeted GLS1 and MEK inhibition enhance antitumor activity in vitro and in vivo.• The therapeutic… Click to show full abstract
Highlights • The glutamine utilization of KRAS-mutant NSCLC is higher than that of KRAS wild-type.• Targeted GLS1 and MEK inhibition enhance antitumor activity in vitro and in vivo.• The therapeutic response can be well identified by 18F-FDG PET imaging.• Dual inhibition of GLS1 and MEK induce redox and energetic stress.• Dual inhibition of GLS1 and MEK suppress the phosphorylation of AKT.
Keywords:
mutant nsclc;
inhibition;
inhibition glutamine;
gls1 mek;
kras mutant;
targeted inhibition
Journal Title: Translational Oncology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Translational Oncology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!